The incidence of differentiated thyroid cancer (DTC) has increased over the last few
decades, though it remains to be a rare disease. The prognosis of DTC is excellent; its …

Treatment of metastatic differentiated thyroid cancer is first based on the use of radioiodine
and thyrotropin-suppressive thyroid hormone treatment. The recent availability of molecular …

Thyroid carcinoma is the most frequent endocrine malignancy and accounts for around 3%
of global cancer incidence. Different histologies and clinical scenarios make necessary a …

Systemic chemotherapies for advanced or metastatic thyroid carcinomas have been of only
limited effectiveness. For patients with differentiated or medullary carcinomas unresponsive …

Papillary and follicular thyroid cancer, together referred to as differentiated thyroid cancer
(DTC), is usually curable when discovered at an early stage. Its management, however, is …

Targeted therapy in thyroid cancer : Current Opinion in Otolaryngology & Head and Neck
Surgery Targeted therapy in thyroid cancer : Current Opinion in Otolaryngology & Head and …

Opinion statement Papillary thyroid cancer (PTC), the most common thyroid malignancy, is
associated with an excellent prognosis. Overall survival is more than 90%. The first-line …

Thyroid cancer continues to exhibit a rising incidence globally, predominantly affecting
women. Despite stable mortality rates, the unique characteristics of thyroid carcinoma …

Dedifferentiated thyroid cancer (DeTC) derived from follicular epithelium is often incurable
because it does not respond to radioiodine, radiotherapy, or chemotherapy. In cases …

Historically, thyroid cancers have received relatively little attention from the medical
oncology community. As recently as the 2005 Annual Meeting of the American Society of …